A study evaluating the safety and effectiveness of Sacituzumab Govitecan with or without Pembrolizumab in metastatic HR+/HER2- breast cancer.

Brief description of study

The research study procedures include: screening for eligibility, research blood collections, at least two research biopsies, paired research stool collections, and study treatment including evaluations and follow up visits.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
breast cancer
Age: Between 18 Years - 99 Years
Gender: All

Male and Female, Age 18 or older, Diagnosis of breast cancer

Updated on 09 Mar 2024. Study ID: 850029

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).